Screening Donors, Fecal Microbiota Transplant Program in Ulcerative Colitis

Exclusion Criteria

• •1. Participating in another intervention study for UC
• •2. Unable to give informed consent
• •3. Severe comorbid medical illness
• •4. Severe UC requiring hospitalization.
• •5. Increase in medical therapy for UC in the last 12 weeks. Continued treatment with 5-ASA, azathioprine, 6-mercaptopurine or anti-TNF therapy (e.g. infliximab) will be permitted if taken at stable dose for ≥12 weeks prior to randomization. Relapse on a stable dose (same dose for at least 2 weeks) or a tapering dose of steroids will also be permitted provided the dose of steroid is not increased again. Stable intake of probiotic therapy also permitted.
• •6. Antibiotic therapy in the last 30 days.
• •7. Pregnant women.
• •8. Patients with clinically significant hepatic dysfunction at the time of screening: ALT \> 5 times the upper normal range.
• •9. Patients with clinically significant renal dysfunction at the time of screening: serum creatinine \> 300 µmol/L
• •10. Any condition, in the opinion of the investigator, that the treatment may pose a health risk to the subject.